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ABSTRACT
Reduced-intensity allogeneic transplantations for myelodysplastic syndrome (MDS) patients have been limited
by significant graft-versus-host disease (GVHD), treatment-related mortality, and disease relapse. We treated
18 MDS patients ineligible for standard allogeneic transplantation with a preparative regimen of photopheresis
day7 and6, pentostatin 4 mg/m2 by continuous infusion day5 and4, and total body irradiation 600 cGy
in 3 fractions day 3 and 2, followed by allogeneic stem cell infusion from 6/6 or 5/6 HLA-matched related
donors or 6/6 HLA-matched unrelated donors. GVHD prophylaxis consisted of cyclosporin A and a short
course of methotrexate. The median age was 54 years (range, 30-70 years). Diagnoses included refractory
anemia (n  2), refractory anemia with ringed sideroblasts (n  2), refractory anemia with excess blasts (n 
10), refractory anemia with excess blasts in transformation (n 3), and chronic myelomonocytic leukemia (n
1). Sixteen of 18 patients developed full donor chimerism with no day100 transplant-related mortality. Grade
II to IV acute GVHD and extensive chronic GVHD developed in 19% and 18% of patients, respectively.
Disease relapse occurred in 2 patients. At a median follow-up of 14 months (range, 1-35 months), the 1-year
failure-free and overall survival were 64% and 65%, respectively. Our photopheresis and pentostatin–based
reduced-intensity preparative regimen for allogeneic bone marrow transplantation in high-risk MDS patients
achieves successful donor engraftment and disease remission with less transplant toxicity and grade II to IV
acute GVHD.
© 2003 American Society for Blood and Marrow Transplantation
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gNTRODUCTION
The myelodysplastic syndromes (MDS) are a het-
rogeneous group of clonal disorders characterized by
neffective hematopoiesis; they manifest clinically as
nemia, neutropenia, and thrombocytopenia [1]. Pa-
ients with the French-American-British (FAB) classi-
cation of refractory anemia with excess blasts
RAEB) or refractory anemia with excess blasts in
ransformation have a median survival of 12 months
2]. Allogeneic stem cell transplantation offers the
nly curative treatment, with an estimated 3-year dis-
ase-free survival probability of 25% in patients with h
B&MTatched unrelated donors and 28% in patients with
atched related donors [3]. However, ablative doses
f chemotherapy and radiation are associated with
igh incidences of treatment-related mortality (TRM)
nd graft-versus-host disease (GVHD), preventing
ost MDS patients from receiving conventional
ransplantation. Reduced-intensity preparative regi-
ens have enabled successful donor engraftment in
DS patients ineligible for conventional transplanta-
ion because of advanced age, poor performance sta-
us, or comorbidities. However, MDS patients under-
oing reduced-intensity transplantation experienceoi:10.1016/j.bbmt.2003.08.002igh incidences of TRM (33%-48%), GVHD (33%-
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43%), and disease relapse (33%-42%), resulting in
poor overall survival (26%-39%) [4-6]. We report the
results of a novel reduced-intensity preparative regi-
men for allogeneic stem cell transplantation in high-
risk MDS patients that combines durable donor en-
graftment and disease remission with minimal TRM
and GVHD.
MATERIALS AND METHODS
Patient Characteristics
Between January 2000 and February 2003, 18
high-risk MDS patients underwent reduced-intensity
allogeneic stem cell transplantation at Tufts–New En-
glandMedical Center (Table 1). The median recipient
age was 54 years (range, 30-70 years). There were 7
men and 11 women. Thirteen patients had primary
MDS, whereas 5 patients developed MDS as a com-
plication of prior therapy for Hodgkin disease (n 2),
non-Hodgkin lymphoma (n  1), breast cancer (n 
1), or multiple myeloma (n  1). Diagnoses by FAB
classiﬁcation included refractory anemia (n  2), re-
fractory anemia with ringed sideroblasts (n  2),
RAEB (n 10), refractory anemia with excess blasts in
transformation (n  3), and chronic myelomonocytic
leukemia (n  1). Classiﬁcation by the International
Prognostic Scoring System (IPSS) [7] included low
(n  1), intermediate-1 (n  9), intermediate-2 (n 
5), and high (n  3). Risk factors for GVHD included
5 of 6 HLA-matched related donors (n  4), 6 of 6
HLA-matched unrelated donors (n  4), granulocyte
colony-stimulating factor–stimulated peripheral blood
stem cells (n 1), female donor to male recipient (n
4), and cytomegalovirus (CMV)–seropositive recipient
(n  10). Two patients underwent prior autologous
stem cell transplantation for multiple myeloma (n 1)
or Hodgkin disease (n  1). Four patients underwent
induction chemotherapy followed immediately by the
preparative regimen, whereas 5 patients underwent
induction chemotherapy followed by marrow recovery
before the preparative regimen was initiated. Patients
were ineligible for conventional allogeneic stem cell
transplantation because of 1 or more of the following
risk factors: age 50 years (n  11), secondary MDS
(n  5), poor performance status from prior chemo-
therapy (n  2), morbid obesity (n  1), or recurrent
bleeding complications (n  3).
Transplant Preparative Regimen, GVHD
Prophylaxis, and Supportive Care
Patients received extracorporeal photopheresis
(ECP) day 7 and 6, pentostatin 4 mg/m2 by con-
tinuous infusion day 5 and 4, and total body irra-
diation 600 cGy in three 200-cGy fractions day 3
and 2. On day 0, unmanipulated allogeneic stem
cells from bone marrow (n  17) or granulocyte col-
ony-stimulating factor–stimulated peripheral blood
(n  1) were infused.
GVHD prophylaxis consisted of cyclosporin A 2.5
mg/kg/d by continuous infusion starting on day 1
and converting to oral cyclosporin A when tolerated,
tapering off after day 100 [8]. Methotrexate 15
mg/m2 was given on day1 and 10 mg/m2 on day3.
Mycophenolate mofetil 1000 mg orally twice per day
was started on day 100 and tapered off after day
365 in the absence of GVHD. Methylprednisolone
Table 1. Patient Characteristics
Patient
No.
Age
(y)/Sex Type/FAB
IPSS
Group BMT Type
Sex
Mismatch
Host/Donor
CMV Status
Prior
BMT Prior Chemotherapy
1 59/M Primary/RAEB High 5/6 Allo Yes / No Induction, recover, then BMT
2 58/M Primary/RAEB Int-1 5/6 Allo Yes / No Induction into BMT
3 70/M Primary/RAEB Int-1 6/6 Allo Yes / No No
4 61/F Secondary/RAEB Int-2 5/6 Allo No / Auto No
5 45/F Primary/RAEB Int-2 6/6 Allo No / No Induction, recover, then BMT
6 59/M Primary/RAEB Int-1 6/6 Allo No / No No
7 32/F Secondary/RAEB Int-1 6/6 Allo Yes / No Induction into BMT
8 35/F Secondary/RAEBT Int-1 6/6 Allo Yes / Auto No
9 41/F Primary/RA Low 6/6 Stem No / No No
10 53/F Primary/CMML Int-1 6/6 Allo Yes / No Induction into BMT
11 60/F Primary/RARS Int-1 6/6 MUD Yes / No Induction, recover, then BMT
12 47/F Primary/RAEB Int-2 6/6 MUD No / No Induction into BMT
13 61/M Primary/RAEB High 5/6 Allo No / No No
14 56/F Primary/RAEBT High 6/6 Allo No / No Induction, recover, then BMT
15 42/F Secondary/RAEBT Int-2 6/6 MUD Yes / No Induction, recover, then BMT
16 51/M Primary/RAEB Int-2 6/6 MUD Yes / No No
17 60/F Secondary/RARS Int-1 6/6 Allo No / No No
18 30/M Primary/RA Int-1 6/6 Allo No / No No
Allo indicates allogeneic bone marrow stem cells; Stem, peripheral blood stem cells; MUD, matched unrelated donor bone marrow stem cells;
Auto, autologous stem cell transplantation; BMT, bone marrow transplantation; Int, intermediate; RAEBT, refractory anemia with excess
blasts in transformation; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts.
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1 mg/kg was used for treatment of GVHD and ta-
pered off when GVHD symptoms resolved.
Antimicrobial prophylaxes were performed ac-
cording to institutional protocols. These included tri-
methoprim/sulfamethoxazole for Pneumocystis carinii
prophylaxis and acyclovir for herpes simplex virus pro-
phylaxis.
Outcomes
Complete response was deﬁned as normal trilin-
eage hematopoiesis with the absence of MDS by bone
marrow biopsy and the absence of circulating blasts.
Progressive disease was deﬁned as the persistence of
MDS morphology by bone marrow biopsy after trans-
plantation or the persistence of circulating blasts. Dis-
ease relapse was deﬁned as the presence of MDS
morphology by bone marrow biopsy or the presence
of circulating blasts after a complete response was
achieved. Chimerism was determined at the time of
neutrophil engraftment by ﬂuorescent in situ hybrid-
ization for the Y chromosome in cases of sex-mis-
matched transplants or by polymerase chain reaction
of polymorphic short tandem repeats in cases of sex-
matched transplants. Clinical response was deﬁned
according to the international working group on stan-
dardizing response criteria in MDS [9]. Standard cri-
teria were used to diagnose and grade acute and
chronic GVHD [10]. Regimen-related toxicity was
graded by using the system of Bearman et al. [11].
Statistics
Transplant-related mortality was deﬁned as any
cause of death in the absence of disease progression
or relapse. Failure-free survival was deﬁned as time
to disease progression or death from any cause.
Failure-free survival and overall survival were esti-
mated with the Kaplan-Meier method. Chi-square
tests were used to examine the association between
various patient characteristics and transplant out-
comes. A P value of .05 was considered statisti-
cally signiﬁcant.
RESULTS
Engraftment and Chimerism
Sixteen (89%) of 18 patients developed full donor
chimerism (90% donor), and 14 patients achieved
full donor chimerism at the time of engraftment (Ta-
ble 2). Two patients reached full donor chimerism by
day 100 without donor lymphocyte infusion. Two
patients did not engraft and had full autologous he-
matopoietic reconstitution. The median time to reach
an absolute neutrophil count 5  108/L for 3 con-
secutive days was 15 days (range, 9-40 days). The
median time to reach a platelet count of 20  109/L
with transfusion independence was 20 days (range,
8-59 days).
Table 2. Patient Results
Patient
No.
Days to ANC
>5  109/L
Days to PLT
>20  109/L
Chimerism at
Engraftment
Acute
GVHD
Chronic
GVHD
Disease
Status
Overall
Status Outcome
1 14 32 99% donor I None CR Alive No chronic GVHD
2 16 54 100% donor II Extensive CR Died Skin chronic GVHD. Died of
cerebrovascular event
3 9 25 99% donor I Limited CR Alive Oral chronic GVHD
4 16 35 Host NA NA PD Died Died of progressive disease
5 12 18 Donor I None CR Alive No chronic GVHD
6 15 22 Donor I Limited CR Alive Oral chronic GVHD
7 24 18 61% donor I Limited CR Died 100% donor by day 91. Skin
chronic GVHD, died of
idiopathic pulmonary
syndrome
8 17 18 95% donor 0 Limited CR Alive No chronic GVHD
9 24 51 Mixed 0 Limited CR Alive 100% donor at day 100. Skin
chronic GVHD
10 16 16 90% donor 0 Extensive CR Alive Skin chronic GVHD
11 11 17 99% donor III Extensive CR Died Died of gut chronic GVHD
12 15 99 Donor IV Extensive CR Died Died of gut chronic GVHD
13 40 59 Host NA NA PD Died Died of progressive disease
14 15 8 Donor I None Relapse Died Died of progressive disease
15 12 16 Donor I None CR Alive No chronic GVHD
16 15 24 Donor 0 None CR Alive No chronic GVHD
17 25 39 Donor 0 NA Relapse Died Died of progressive disease
18 24 27 Donor I None CR Alive No chronic GVHD
ANC indicates absolute neutrophil count; PLT, platelet count; CR, complete response; PD, progressive disease; NA, not applicable.
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Graft-versus-Host Disease
Thirteen patients (81%) had grade 0 (n  5) or I
(n  8) acute GVHD. One patient developed grade
III acute GVHD of the skin, and 2 patients developed
grade III or IV acute GVHD of the gut, for an overall
19% incidence of grade II to IV acute GVHD. No
one died from acute GVHD before day 100. Eight
patients (53%) had no evidence of chronic GVHD.
Limited chronic GVHD developed in 4 patients
(27%), and extensive chronic GVHD of the skin de-
veloped in 3 patients (20%).
Transplant Toxicity
According to the Bearman score, no patients ex-
perienced grade 3 or 4 mucositis, liver, or renal tox-
icity. Grade 1 or 2 mucositis was seen in 9 and 2
patients, respectively. Ten patients had grade 1 liver
toxicity, and 1 patient had grade 2 liver toxicity. Grade
2 renal toxicity was seen in 1 patient, and grade 1 renal
toxicity was seen in 10 patients. No patient experi-
enced veno-occlusive disease. CMV reactivation was
seen in only 3 patients (17%), and all were successfully
treated with valganciclovir therapy. No one died of
transplant-related complications before day 100.
The 1-year TRM was 14%. There were 8 deaths in
this study. Three patients died from complications
related to extensive chronic GVHD while in complete
remission. One patient in complete remission died of
idiopathic pulmonary syndrome 19 months after
transplantation. Both patients whose donor engraft-
ment failed died of disease progression. Two patients
who had donor engraftment died of disease relapse.
Response and Survival
Out of 16 patients who demonstrated durable do-
nor engraftment, 14 patients (88%) achieved clinical
complete remission with the absence of circulating or
bone marrow blasts and normal trilineage hematopoi-
esis. Two patients (13%) developed disease relapse 39
and 117 days after donor engraftment. Both patients
died of disease progression before donor lymphocyte
infusion could be given. After a median follow-up of
14 months (range, 1-35 months), the 1-year failure-
free survival was 64% (Figure 1). The 1-year overall
survival was 65% (Figure 2). Ten patients were alive
and free from clinical disease at the time of analysis.
Prognostic Factors
GVHD severity and overall survival were not
markedly different by FAB subtypes, IPSS scores, or
patient age (Table 3). However, MDS patients who
received transplants from 6 of 6 HLA-matched related
donors had a lower incidence of grade II to IV acute
GVHD as compared with mismatched related and
matched unrelated donors (0% versus 50%; P  .01)
and had better 1-year overall survival (71% versus
57%; P  .19; Figure 3). The incidence of disease
relapse did not differ in the setting of grade II to IV
acute GVHD (15% versus 0%; P  .47) or limited or
extensive chronic GVHD (14% versus 0%; P  .27).
DISCUSSION
Conventional allogeneic stem cell transplantation,
although curative for MDS patients, is associated with
successful donor engraftment (91%) and a low inci-
dence of disease relapse (17%) but with high inci-
dences of TRM (37%), grade II to IV acute GVHD
(36%), and chronic GVHD (39%), resulting in a
3-year disease-free and overall survival of only 23%
and 40%, respectively [12]. Reduced-intensity prepar-
ative regimens rely on host immunosuppression in-
stead of ablative doses of chemoradiation to minimize
TRM while facilitating donor stem cell engraftment
to achieve disease remission through a graft-versus-
tumor effect. However, ﬂudarabine-based reduced-
intensity preparative regimens for allogeneic trans-
Figure 1. Failure-free survival in patients with MDS after the
photopheresis and pentostatin reduced-intensity preparative regi-
men.
Figure 2. Overall survival in patients with MDS after the photo-
pheresis and pentostatin reduced-intensity preparative regimen.
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plantation of MDS patients were complicated by high
incidences of TRM (27%-48%), grade II to IV acute
GVHD (33%-75%), chronic GVHD (38%-48%),
and disease relapse (25%-33%), resulting in poor dis-
ease-free survival (12%-38%) and overall survival
(26%-39%) [4-6,13].
In contrast, MDS patients who underwent a pho-
topheresis and pentostatin–based conditioning regi-
men achieved early full donor chimerism with no
100-day TRM, 19% grade II to IV acute GVHD, and
a 13% disease relapse rate, resulting in a 65% overall
survival. Prompt establishment of full donor chimer-
ism seems important in harnessing a maximum graft-
versus-leukemia effect [14], and this was achieved with
low transplant-related toxicity and no TRM. Our fail-
ure-free and overall survival were markedly higher
than in a similar cohort of patients reported by Kroger
et al. [6]. Although our study examined a small num-
ber of patients at a single institution, patient charac-
teristics are unlikely to explain the different outcomes
because the numbers of patients with older age, RAEB
classiﬁcation, and aberrant cytogenetics were similar
in both studies.
The 19% incidence of severe grade II to IV acute
GVHDwas also markedly lower than the 33% to 75%
reported in other reduced-intensity preparative regi-
mens for MDS patients [5,6,13-16]. Although more
patients received stem cells from matched unrelated
donors in the study from Kroger et al., the patients we
treated were at higher risk for GVHD because of
advanced age, single antigen–mismatched related do-
nors, and CMV recipient seropositivity, making the
risk of GVHD similar in both groups. Stem cell
source was unlikely to be the cause for the differences
in GVHD because both studies used bone marrow
stem cells. Successful donor engraftment in most pa-
tients and the low incidence of CMV reactivation
suggest that the low incidence of GVHD was not
achieved with excessive immunosuppression alone.
Therefore, the reason why our regimen has a mark-
edly lower incidence of severe acute GVHD may be
related to our novel preparative regimen.
The pathophysiology of acute GVHD is complex
and involves the release of host antigens after damage
to host tissues with the preparative regimen; it also
involves the presentation of host antigens by host
dendritic cells (DCs) to donor T cells in the context of
major histocompatibility complex molecules to acti-
vate CD8 cells, thereby initiating the proinﬂamma-
tory cytokine cascade [17]. In murine studies, inacti-
vation of host DCs before transplantation abrogated
GVHD, suggesting that host DCs that linger after
transplantation may play an important role in the
pathogenesis of acute GVHD [18]. In human trans-
plants, alemtuzumab given before transplantation has
been shown to deplete circulating host DCs, resulting
in the absence of host DCs and a low incidence of
acute posttransplantation GVHD [19]. However, the
low rate of acute GVHD may also be related to the
effects of in vivo T-cell depletion by the prolonged
half-life of alemtuzumab, resulting in increased inci-
Figure 3. Overall survival by donor match in patients with MDS
after the photopheresis and pentostatin reduced-intensity prepara-
tive regimen. The top curve represents 6 of 6 matched related
donors. The bottom curve includes 5 of 6 matched related donors
and 6 of 6 matched unrelated donors (1-year overall survival, 71%
versus 57%; P  .19)
Table 3. Prognostic Factors*
Factor
Grade II-IV
Acute GVHD
1-Year Overall
Survival
FAB subtypes
RAEB or RAEBT 18% 68%
Others 20% 53%
P value .93 .61
IPSS groups
Low or intermediate-1 17% 79%
Intermediate-2 or high 20% 45%
P value .87 .42
Age
<50 y 14% 83%
>50 y 22% 52%
P value .69 .26
Induction chemotherapy
Yes 33% 67%
No 0% 62%
P value .09 .96
Donor match
6/6 matched related donors 0% 71%
Mismatched related donors
or matched unrelated
donors 50% 57%
P value .01 .19
RAEBT indicates refractory anemia with excess blasts in transfor-
mation.
*The incidence of grade II-IV acute GVHD and 1-y overall survival
did not differ signiﬁcantly when subdivided by FAB classiﬁca-
tion, IPSS groups, age, or prior induction chemotherapy. Donor
match signiﬁcantly increased the incidence of grade II-IV acute
GVHD but did not affect 1-y overall survival.
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dences of engraftment failure, CMV reactivation, and
disease relapse [20].
ECP involves the ex vivo exposure of leukaphere-
sed peripheral blood mononuclear cells to ultraviolet
A light in the presence of a DNA-intercalating agent,
8-methoxypsoralen, with subsequent reinfusion of
treated cells. The total number of lymphocytes treated
ex vivo per cycle has been estimated to be between 5%
and 15% of the total circulating lymphocytes, and the
total energy delivered via ultraviolet A light is esti-
mated to be 2 J/cm2 per lymphocyte [21]. ECP has
been used successfully to treat acute and chronic
GVHD that is refractory to conventional immuno-
suppression [22,23]. In the treatment of chronic
GVHD, ECP decreases the number of DCs while
shifting from DC1 subtypes that promote proinﬂam-
matory cytokine secretion to DC2 subtypes that are
associated with immune tolerance [24]. DC chimerism
studies in patients after our ECP and pentostatin–
based preparative regimen demonstrated that the
absence of severe acute and chronic GVHD was as-
sociated with the absence of host DCs after transplan-
tation, whereas the persistence of host DCs after
transplantation was associated with severe acute and
extensive chronic GVHD [25]. Decreases in DC1 and
DC2 numbers after ECP in the preparative regimen
have been observed in patients who remain in com-
plete remission in the absence of host DCs or GVHD
after transplantation [26].
No signiﬁcant differences in the incidence of
grade II to IV acute GVHD or in overall survival were
observed between FAB subtypes, IPSS groups, or age,
suggesting that patients with advanced MDS tolerate
this preparative regimen as well as patients with less
advanced MDS. Remarkably, there was no difference
in overall survival between patients who underwent
transplantation directly and patients who required in-
duction chemotherapy before transplantation for in-
creasing blast counts, suggesting that induction che-
motherapy before transplantation did not increase
toxicity or mortality. As expected, transplants from
mismatched related donors and matched unrelated
donors resulted in a signiﬁcantly higher incidence of
grade II to IV acute GVHD, although the difference
in overall survival was not signiﬁcantly different. The
absence of signiﬁcant differences in overall survival
between transplants with 6/6 matched related donors
and HLA class I mismatched or matched unrelated
donors suggests that the degree of donor match may
not have an adverse effect on transplantation out-
comes after this preparative regimen.
In contrast to a study by Martino et al. [13],
disease remission in our study was not associated with
development of acute or chronic GVHD. In fact, 8 of
10 patients with 6 of 6 matched related donors re-
mained in complete remission without developing
grade II to IV acute GVHD, suggesting that preven-
tion of GVHD was not accomplished by compromis-
ing graft-versus-tumor effects. The low incidence of
CMV reactivation also suggests that the low incidence
of severe GVHD was not achieved through excessive
impairment of immune function. The role that ECP
and pentostatin play in reducing host DCs before
transplantation and their effects on preventing the
development of grade II to IV acute GVHD merit
further investigation.
We acknowledge that the limited number of pa-
tients and early follow-up preclude any deﬁnitive con-
clusions. Further studies are needed to evaluate the
role of ECP in modulating DCs and preventing the
development of GVHD. However, we conclude that
our photopheresis and pentostatin–based reduced-in-
tensity preparative regimen enables patients with
MDS to beneﬁt from allogeneic stem cell transplan-
tation with minimal GVHD, transplant-related toxic-
ity, and mortality. The curative potential of this ap-
proach requires further exploration.
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